Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$229.07 USD

229.07
747,663

-5.46 (-2.33%)

Updated Sep 18, 2024 12:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

by Zacks Equity Research

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

by Zacks Equity Research

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

by Zacks Equity Research

The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).

Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery

by Zacks Equity Research

Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.

Here's Why You Should Retain HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) strength in HSAs raises optimism about the stock.

Cencora (COR) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research

by Zacks Equity Research

Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.

High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio

by Zacks Equity Research

High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.

Labcorp (LH) Presents New Research on Precision Diagnostics

by Zacks Equity Research

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow

by Zacks Equity Research

GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

by Zacks Equity Research

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Intuitive Surgical's (ISRG) Da Vinci 5 Receives FDA Approval

by Zacks Equity Research

Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.

BD's (BDX) ADC System Favored by New Study for Long-Term Care

by Zacks Equity Research

BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

by Zacks Equity Research

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?

by Zacks Equity Research

Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.

Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON

by Zacks Equity Research

Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.

UnitedHealth's (UNH) Payment System Disrupted by Cyberattack

by Zacks Equity Research

A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.

AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex

by Zacks Equity Research

AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.